We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


BioWa and OncoTherapy Collaborate to Develop Anticancer Monoclonal Antibodies

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

BioWa, Inc. and OncoTherapy Science, Inc. have announced that the two companies have entered into a collaboration to identify and develop cancer- focused monoclonal antibodies (Mabs).

OncoTherapy Science will employ its technology for identification of the cancer antigens and generation of Mabs against those antigens, and BioWa will apply its POTELLIGENT™ technology to the Mabs for the enhancement of antibody-dependent cellular cytotoxicity (ADCC).

The collaboration is expected to create antibody therapeutics with improved biological properties targeting newly discovered membrane antigens.

Under this collaboration, BioWa and OncoTherapy Science will carry out research and development activities collaboratively and will share profits gained from future antibody products.

“We are pleased to be working with OncoTherapy Science,” said Dr. Nobuo Hanai, President and CEO of BioWa.

“Our partnership with OncoTherapy Science gives us the opportunities to strengthen our portfolio for ADCC-enhanced Mab programs.”

“We are delighted to announce our collaboration with BioWa, who is highly experienced in research and development of Mabs,” stated Mr. Kensuke Tomita, President and CEO of OncoTherapy Science.

He adds, “Combining two companies' expertise will build an excellent foundation for a productive partnership.”